Cambridge Healthtech Institute’s 6th Annual

Target Validation and Phenotypic Screening

Part of 19th Annual World Preclinical Congress

June 17, 2021

 

Finding and validating novel, druggable targets for therapeutic intervention remains a top priority for the pharma/biotech industry. Phenotypic drug discovery tackles disease complexity and promises to deliver first-in-class drug targets. Cambridge Healthtech Institute’s 6th Annual Target Validation and Phenotypic Screening conference will bring together leading experts to discuss cell-based phenotypic screening, hit validation and target deconvolution, high-content screening and chemical genomics, target validation and translational strategies.

 

Coverage will include, but is not limited to:

 

  • Phenotypic drug discovery (PDD)
  • Cell-based phenotypic screening
  • High-content analysis and imaging
  • Hit validation and target deconvolution
  • Defining a cellular disease phenotype
  • Target validation and translational approaches
  • Chemoproteomics and chemogenomics

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is January 29, 2021.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:

Julia Boguslavsky

Executive Director, Conferences

Cambridge Healthtech Institute

Email: juliab@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-247-6286

Email: reymael@healthtech.com